Ipsen and Biomunex announce exclusive global licensing agreement for first-in-class MAIT cell engager in immuno-oncology
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 03 2024
0mins
Source: Yahoo Finance
Ipsen's Licensing Agreement: Ipsen has secured exclusive global rights to develop and commercialize BMX-502, a bispecific antibody targeting MAIT cells and the GPC3 tumor antigen, which shows promise in treating various solid tumors.
Potential Benefits of BMX-502: The innovative MAIT-engager approach aims to enhance anti-tumor activity while minimizing side effects associated with traditional T cell therapies, potentially offering a more effective treatment option for cancer patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
